NASDAQ: TRVI
Trevi Therapeutics Inc Stock Ownership - Who owns Trevi Therapeutics?

Insider buying vs selling

Have Trevi Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Thomas SciasciaChief Scientific Officer2025-03-252,631$6.60
$17.36kSell
Thomas SciasciaChief Scientific Officer2025-03-252,631$1.43
$3.76kBuy
Jennifer L. GoodPresident CEO2025-03-215,263$1.43
$7.53kBuy
Jennifer L. GoodPresident CEO2025-03-215,263$6.58
$34.63kSell
Farrell SimonChief Commercial Officer2025-03-104,350$7.15
$31.10kSell
Farrell SimonChief Commercial Officer2025-03-1017,500$3.21
$56.18kBuy
Farrell SimonChief Commercial Officer2025-03-1063,813$3.91
$249.51kBuy
Farrell SimonChief Commercial Officer2025-03-1031,250$0.51
$15.97kBuy
Farrell SimonChief Commercial Officer2025-03-1076,963$6.73
$517.81kSell
Lisa DelfiniChief Financial Officer2025-01-085,000$0.51
$2.56kBuy

1 of 4

TRVI insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TRVI insiders and whales buy or sell their stock.

TRVI Shareholders

What type of owners hold Trevi Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ali Behbahani17.90%17,308,374$114.06MInsider
Mohamad Makhzoumi17.90%17,308,374$114.06MInsider
Carmen Chang17.90%17,308,374$114.06MInsider
Anthony A. Florence Jr.17.90%17,308,374$114.06MInsider
Scott D. Sandell17.90%17,308,374$114.06MInsider
Paul Edward Walker17.90%17,308,374$114.06MInsider
Peter W. Sonsini17.90%17,308,374$114.06MInsider
Forest Baskett16.92%16,359,426$107.81MInsider
Nea Management Company LLC11.76%11,370,376$74.93MInstitution
Frazier Life Sciences Management LP11.03%10,664,774$70.28MInstitution

1 of 3

TRVI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TRVI30.28%69.72%Net BuyingNet Buying
NAGE13.74%86.26%Net BuyingNet Buying
CRMD35.21%10.21%Net SellingNet Buying
IMTX75.92%0.00%
KROS70.41%29.59%Net BuyingNet Buying

Trevi Therapeutics Stock Ownership FAQ

Who owns Trevi Therapeutics?

Trevi Therapeutics (NASDAQ: TRVI) is owned by 82.18% institutional shareholders, 189.27% Trevi Therapeutics insiders, and 0.00% retail investors. Ali Behbahani is the largest individual Trevi Therapeutics shareholder, owning 17.31M shares representing 17.90% of the company. Ali Behbahani's Trevi Therapeutics shares are currently valued at $109.22M.

If you're new to stock investing, here's how to buy Trevi Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.